NOVEL RETINOIDS FOR EMPHYSEMA TREATMENT Russian patent published in 2006 - IPC C07C65/28 C07C323/56 C07D231/12 C07D207/32 C07D307/38 C07C65/19 C07D295/08 C07D239/38 C07D249/12 A61K31/19 A61K31/33 A61P11/00 A61P17/00 A61P35/00 

Abstract RU 2282616 C2

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to novel retinoid compounds of the structural formula (I) or their pharmaceutically acceptable salts and pharmaceutical compositions possessing agonistic activity with respect to retinoid receptors and comprising indicated compounds wherein n = 1; d = 0 or 1; B means -CR7=CR8-, -CH2O- wherein R7 and R8 each means independently hydrogen atom; X means phenyl optionally substituted with halogen atom, or 5-membered heteroaryl comprising sulfur atom (S) as a heteroatom; R1 means -C(=O)-R9 wherein R9 means alkyl, hydroxyl, amino-, heteroaryloxy-group comprising oxygen atom (O) or 6-membered heterocyclyl comprising nitrogen atom (N) as a heteroatom; R2 means: (a) -(CR10R11)m-Yp-R12; m means a whole number from 1 to 10; p means 0 or 1; R10 and R11 mean hydrogen atom; Y means -O-, -S- or -NR13-; R13 means hydrogen atom; R12 means hydrogen atom, alkyl, cycloalkyl, phenyl, 5- or 6-membered heteroaryl comprising atoms N, S, O as a heteroatom, 5- or 6-membered heteroarylalkyl comprising atoms N, S, O as a heteroatom, heteroalkyl comprising atoms N, S, O as a heteroatom, 5- or 6-membered heterocyclyl comprising atoms N, S, O as a heteroatom, or 5- or 6-membered heterocyclylalkyl comprising atoms N, S, O as a heteroatom under condition that when p means 0 then R12 doesn't mean hydrogen atom or alkyl; (b) 5- or 6-membered heteroaryl comprising atoms N, S, O as a heteroatom; (c) -Z-L wherein Z means -CR14=CR15-, -C≡C-, -C(=O) or -S-; R14 and R15 mean hydrogen atom; L means 5- or 6-membered heteroaryl comprising atoms N, S, O as a heteroatom; (d) -CR14=CR15-L1 wherein L1 means -S(O)2R17 or -SO2NR18R19 wherein R17 means alkyl; R18 and R19 mean hydrogen atom; each R3 means independently hydrogen atom, hydroxyl or oxo-group; t means 1 or 2.

EFFECT: valuable medicinal properties of compounds and compositions.

59 cl, 10 tbl, 54 ex

Similar patents RU2282616C2

Title Year Author Number
DERIVATIVES OF SUBSTITUTED UREA, PHARMACEUTICAL COMPOSITION AND DRUG BASED ON THEREOF POSSESSING RETINOID ACTIVITY 2002
  • Klaus Mikhaehl'
  • Lap'Er Zhan-Mark
RU2303027C2
DERIVATIVES OF ALKYLUREA POSSESSING PROPERTY OF RETINOID AGONIST, PHARMACEUTICAL COMPOSITION AND MEDICINAL AGENT 2002
  • Belloni Pola Nanette
  • Kertesh Denis Dzhon
  • Klaus Mikhaehl'
  • Lap'Er Zhan-Mark
RU2299877C2
AROMATIC DERIVATIVES OF CARBOXYLIC ACID AND A PHARMACEUTICAL COMPOSITION 1994
  • Mikhaehl' Klaus
  • Peter Mor
RU2130009C1
METHODS OF THERAPY BY APPLYING THE COMPOUNDS EITHER OF SPECIFIC OR SELECTIVE ACTIVITY TO RETINAL ACID RECEPTOR RAR 1996
  • Teng Min
  • Duong Tien T.
  • Chandraratna Roshanta A.
RU2191009C2
RETINOIC ACID X-RECEPTOR LIGANDS 1995
  • Mikhaehl' Klaus
  • Allen Dzhon Lovi
  • Peter Mor
  • Majkl Rozenberger
RU2146241C1
BIAROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS BASED ON THEREOF 1998
  • Bernardon Zhan-Mishel'
  • Diaz Filipp
RU2185373C2
BICYCLIC AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITION CONTAINING THEREOF 1995
  • Zhan-Mishel' Bernardon
RU2141471C1
ARYL- OR HETEROARYLAMIDES OF TETRAHYDRONAPHTHALENE-, CHROMAN-, THIOCHROMAN- AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS SHOWING RETINOID-LIKE BIOLOGICAL ACTIVITY 1996
  • Teng Min
  • Duong Tien T.
  • Chandraratna Roshanta A.
RU2163906C2
COMPOUNDS EXHIBITING SELECTIVITY WITH RESPECT TO RETINOID RECEPTORS, PHARMACEUTICAL COMPOSITION (VARIANTS), METHOD OF MODULATION OF PROCESSES (VARIANTS), METHOD OF SUPPRESSION OF PATHOLOGICAL STATES 1993
  • Markus F.Boehm
  • Richard A.Khejman
  • Lin Tskhi
RU2144913C1
THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS 2013
  • Kimura Kazukhiro
RU2659203C2

RU 2 282 616 C2

Authors

Lap'Er Zhan-Mark

Rotstehjn Dehjvid Mark

Sjogren Ehrik Brajan

Dates

2006-08-27Published

2001-09-24Filed